Keywords: phase, iii, results, copolymer, disappointing, teva, copaxone
Phase III Results For Copolymer 1 Disappointing
Article | 17 October 1994
Teva's Copaxone (copolymer 1) demonstrated a 24% reduction in relapse rates over two years compared to placebo in relapse-remitting multiple sclerosis patients, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
